Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model
AUTOR(ES)
Zhang, Bin
FONTE
National Academy of Sciences
RESUMO
We tested the hypothesis that microtubule (MT)-binding drugs could be therapeutically beneficial in tauopathies by functionally substituting for the MT-binding protein tau, which is sequestered into inclusions of human tauopathies and transgenic mouse models thereof. Transgenic mice were treated for 12 weeks with weekly i.p. injections of 10 or 25 mg/m2 paclitaxel (Paxceed). Both doses restored fast axonal transport in spinal axons, wherein MT numbers and stable (detyrosinated) tubulins were increased, compared with sham treatment, and only Paxceed ameliorated motor impairments in tau transgenic mice. Thus, MT-stabilizing drugs could have therapeutic potential for treating neurodegenerative tauopathies by offsetting losses of tau function that result from the sequestration of this MT-stabilizing protein into filamentous inclusions.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=544048Documentos Relacionados
- Competition for Microtubule-binding with Dual Expression of Tau Missense and Splice Isoforms
- BIM1 Encodes a Microtubule-binding Protein in Yeast
- Dynein and kinesin share an overlapping microtubule-binding site
- Functional Elements within the Dynein Microtubule-binding Domain
- Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains.